A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

Model-based Analysis of ChIP-Seq (MACS)

Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556

Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities

Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382

PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197

Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position

Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening

Shishodia, S., Nuñez, R., Strohmier, B. P., Bursch, K. L., Goetz, C. J., Olp, M. D., Jensen, D. R., Fenske, T. G., Ordonez‐Rubiano, S. C., Blau, M. E., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00864 · Cited by 24

High-content CRISPR screening in tumor immunology

Holcomb, E. A., Pearson, A. N., Jungles, K. M., Tate, A., James, J. G., Jiang, L., Huber, A. K., & Green, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041451 · Cited by 24

Epigenetic modulation by targeting bromodomain containing protein 9 (BRD9): Its therapeutic potential and selective inhibition

Ali, M. M., Naz, S., Ashraf, S., Knapp, S., & Ul‐Haq, Z. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123428 · Cited by 25

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma

Yan, H., Jiang, A., Huang, Y., Zhang, J., Yang, W., Zhang, W., & Liu, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1265914 · Cited by 24

TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer

Zorea, J., Motro, Y., Mazor, R. D., Carmi, Y. K., Shulman, Z., Mahajna, J. A., Moran‐Gilad, J., & Elkabets, M. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02680-7 · Cited by 24

Potentiating anti-tumor immunity by re-engaging immune synapse molecules

Zhou, X., Xu, T., Li, C., He, Y., Hu, Y., Gong, H., Li, J., Jiang, H., Wen, L., Fu, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101975 · Cited by 23

Recent progress in therapeutic antibodies for cancer immunotherapy

Lee, A., Sun, S. W., Sandler, A. B., & HOANG, T. N. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.006 · Cited by 23

Synthetic immunity by remote control

Gamboa, L., Zamat, A. H., & Kwong, G. A. (2020) · Theranostics · doi:10.7150/thno.41305 · Cited by 22

PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIPL to promote TNFα-mediated cell death

Wu, G., Li, D., Liang, W. P., Sun, W., Xie, X., Tong, Y., Shan, B., Zhang, M., Lu, X., Yuan, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05206-9 · Cited by 24

Myeloid checkpoints for cancer immunotherapy

Qian, Y., Yang, T., Liang, H., & Deng, M. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.05.07 · Cited by 24

ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF-κB axis

Meškytė, E. M., Pezzè, L., Bartolomei, L., Forcato, M., Bocci, I. A., Bertalot, G., Barbareschi, M., Oliveira‐Ferrer, L., Bisio, A., Bicciato, S., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05718-y · Cited by 23

Applications of CRISPR-Cas in Bioengineering, Biotechnology, and Translational Research

Lau, C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0026 · Cited by 22

CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients

Liu, T., Xia, Q., Zhang, H., Wang, Z., Yang, W., Gu, X., Hou, T., Chen, Y., Pei, X., Zhu, G., et al. (2020) · Aging · doi:10.18632/aging.103999 · Cited by 23

Network Medicine‐Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD‐L1 Expression via Targeting SPOP in Cancer

Tian, S., Xu, M., Geng, X., Fang, J., Xu, H., Xue, X., Hu, H., Zhang, Q., Yu, D., Guo, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202410285 · Cited by 24

Interrogating immune cells and cancer with CRISPR-Cas9

Buquicchio, F. A., & Satpathy, A. T. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.003 · Cited by 21

Transcriptional determinants of cancer immunotherapy response and resistance

Gupta, R., Mehta, A., & Wajapeyee, N. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.008 · Cited by 23

Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Ito, Y., Pan, D., Zhang, W., Zhang, X., Juan, T. Y., Pyrdol, J. W., Kyrysyuk, O., Doench, J. G., Liu, X. S., & Wucherpfennig, K. W. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1125 · Cited by 23

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment

Luo, H., Wang, W., Mai, J., Yin, R., Cai, X., & Li, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267918 · Cited by 22

Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma

Kamal, Y., Cheng, C., Frost, H. R., & Amos, C. I. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500106 · Cited by 23

Have Cells Harboring the HIV Reservoir Been Immunoedited?

Huang, S.-H., McCann, C. D., Mota, T. M., Wang, C., Lipkin, S. M., & Jones, R. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01842 · Cited by 23

CD8+ T Cell-Based Molecular Classification With Heterogeneous Immunogenomic Landscapes and Clinical Significance of Clear Cell Renal Cell Carcinoma

Wu, X., Jiang, D., Liu, H., Lu, X., Lv, D., & Li, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745945 · Cited by 23

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness

Lin, C., Levy, P. L., Alflen, A., Apriamashvili, G., Ligtenberg, M. A., Vredevoogd, D. W., Bleijerveld, O. B., Alkan, F., Malka, Y., Hoekman, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.016 · Cited by 21

Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma

Sun, Y., Liu, Y., Li, R., Zhang, C., Wu, M., Zhang, X., Zheng, A., Liao, N., Zheng, Y., Xu, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202400951 · Cited by 21

From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures

Tseng, Y., & Boehm, J. S. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.007 · Cited by 21

Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma

Kong, S.-K., Kim, B. S., Lim, H., Kim, H. J., & Kim, Y. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00703-5 · Cited by 24

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions

Zhang, P., Zhang, Y., & Ji, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927132 · Cited by 23

New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)

Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 22

Advancements in CRISPR screens for the development of cancer immunotherapy strategies

Li, Y.-R., Lyu, Z., Tian, Y., Fang, Y., Zhu, Y., Chen, Y., & Yang, L. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.100733 · Cited by 23

Emerging roles of TBK1 in cancer immunobiology

Miranda, A., Shirley, C. A., & Jenkins, R. W. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.007 · Cited by 22

PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenancePreprint

Feng, H., Lane, K. A., Roumeliotis, T. I., Jeggo, P. A., Somaiah, N., Choudhary, J. S., & Downs, J. A. (2022) · Genes & Development · doi:10.1101/gad.349249.121 · Cited by 23

Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy

Zhang, X., Cheng, C., Sun, W. C., & Wang, H. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_23 · Cited by 20

The role of small molecules in cell and gene therapy

Brayshaw, L. L., Martinez-Fleites, C., Athanasopoulos, T., Southgate, T. D., Jespers, L. S., & Herring, C. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00221f · Cited by 21

Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

Kinoshita, T., Terai, H., & Yaguchi, T. (2021) · Life · doi:10.3390/life11101029 · Cited by 24

Tumor evolution selectively inactivates the core microRNA machinery for immune evasion

Song, T., Long, M., Zhao, H., Zou, M.-W., Fan, H., Liu, Y., Geng, C., Song, M., Liu, Y.-F., Chen, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27331-3 · Cited by 20

PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers

Lee, D.-H., Jeong, Y. J., Won, J., Sim, H.-I., Park, Y., & Jin, H. (2022) · Biomedicines · doi:10.3390/biomedicines10020299 · Cited by 21

Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer

Shin, D. S., Park, K., Garon, E. B., & Dubinett, S. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.005 · Cited by 20

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 22

Cancer research in the era of immunogenomics

Wolf, Y., & Samuels, Y. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000475 · Cited by 20

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response

Murphy, C., Muscat, A. M., Ashley, D. M., Mukaro, V. R., West, L., Liao, Y., Chisanga, D., Shi, W., Collins, I. M., Baron-Hay, S. E., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210891 · Cited by 22

Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer

Davra, V., Saleh, T., Geng, K., Kimani, S. G., Mehta, D., Kasikara, C., Smith, B. C., Colangelo, N. W., Ciccarelli, B. T., Li, H., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1144 · Cited by 19

Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation

Sorrentino, A., Menevse, A. N., Michels, T., Volpin, V., Durst, F. C., Sax, J., Xydia, M., Hussein, A., Stamova, S., Spoerl, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004258 · Cited by 21

New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy

Oberholtzer, N. P., Quinn, K. M., Chakraborty, P., & Mehrotra, S. (2022) · Cells · doi:10.3390/cells11040708 · Cited by 19

Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

Cheng, C.-Y., Chen, C., & Wu, C. (2022) · Life · doi:10.3390/life12060829 · Cited by 19

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates

Seyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 23

PBRM1 bromodomains associate with RNA to facilitate chromatin association

Silva, S. M. D., Dhiman, A., Sood, S., Mercedes, K. F., Simmons, W. J., Henen, M. A., Vögeli, B., Dykhuizen, E. C., & Musselman, C. A. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad072 · Cited by 19

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation

Li, C., Wang, Z., Yao, L., Lin, X., Jian, Y., Li, Y., Zhang, J., Shao, J., Tran, P. D., Hagman, J. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46422-5 · Cited by 22

TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

Sun, Y., Maggs, L., Panda, A., Wright, S. J., Cicerchia, A. M., Jenney, A., Perricone, M. D., Mills, C. E., Cattaneo, G., Ventin, M., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1011 · Cited by 17

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 20

Predicting immunotherapy response through genomics

Cormedi, M. C. V., Allen, E. M. V., & Colli, L. M. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.11.004 · Cited by 19

Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma

McGeary, M. K., Damsky, W., Daniels, A. J., Lang, S. M., Xu, Q., Song, E., Huet-Calderwood, C., Lou, H. J., Paradkar, S., Micevic, G., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0514 · Cited by 19

Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis

Cantini, L., Pecci, F., Murrone, A., Tomasetti, M., Copparoni, C., Fiordoliva, I., Morgese, F., Rinaldi, S., Mazzanti, P., Rubini, C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.024 · Cited by 18

SWI/SNF Chromatin Remodeling Enzymes in Melanoma

Dreier, M. R., & de la Serna, I. L. (2022) · Epigenomes · doi:10.3390/epigenomes6010010 · Cited by 20

Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT)

Tran, S., Plant, A., Chi, S. N., & Narendran, A. (2023) · Neuro-Oncology Practice · doi:10.1093/nop/npad005 · Cited by 18

Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future perspectives

Shinno, Y., & Ohe, Y. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad175 · Cited by 17

Analysis of the transcriptomic features of microsatellite instability subtype colon cancer

Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5802-2 · Cited by 17

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer

Lee, Y. J., Lee, J. B., Ha, S., & Kim, H. R. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0044 · Cited by 18

The Growing Relevance of Immunoregulation in Pediatric Brain Tumors

Melcher, V., & Kerl, K. (2021) · Cancers · doi:10.3390/cancers13225601 · Cited by 17

Aneuploidy tolerance caused by BRG1 loss allows chromosome gains and recovery of fitness

Schiavoni, F., Zuazua‐Villar, P., Roumeliotis, T. I., Benstead-Hume, G., Pardo, M., Pearl, F. M. G., Choudhary, J. S., & Downs, J. A. (2022) · Nature Communications · doi:10.1038/s41467-022-29420-3 · Cited by 18

A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation

Jin, Y., Huang, R.-J., Guan, W., Wang, Z.-Q., Mai, Z.-J., Li, Y., Xiao, J., Zhang, X., Zhao, Q., Chen, S., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01939-5 · Cited by 19

Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer

Cho, N., Kim, S.-Y., Lee, S., Park, C., Choi, S., Kim, E.-M., & Kim, K. K. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00262-7 · Cited by 18

EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells

Zhu, C., Zhai, T., Su, M., Pan, H., Tang, Q., Huang, B., Chi, X.-R., Li, N., Xie, L.-H., Qiu, S.-Q., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07341-9 · Cited by 19

Genome editing of immune cells using CRISPR/Cas9

Kim, S., Hupperetz, C., Kim, C. H., & Kim, C. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.245 · Cited by 21

USP2 Inhibits Lung Cancer Pathogenesis by Reducing ARID2 Protein Degradation via Ubiquitination

Zhu, L., Chen, Z., Guo, T., Chen, W., Zhao, L., Guo, L., & Pan, X. (2022) · BioMed Research International · doi:10.1155/2022/1525216 · Cited by 17

Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy

Shi, Y., & Shin, D. S. (2023) · Biomolecules · doi:10.3390/biom13060984 · Cited by 18

Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy

Li, M., Sun, J., & Shi, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1220376 · Cited by 20

Exosomes as a Therapeutic Strategy in Cancer: Potential Roles as Drug Carriers and Immune Modulators

Abedi, A., Moghaddam, M. M., Kachuei, R., & Fooladi, A. A. I. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189238 · Cited by 18

The chromatin remodeler SRCAP promotes self‐renewal of intestinal stem cells

Ye, B., Yang, L., Qian, G., Liu, B., Zhu, X., Zhu, P., Ma, J., Xie, W., Li, H., Lu, T., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103786 · Cited by 18

https://cdrjournal.com/article/view/3531

Moreira, M., Pobel, C., Epaillard, N., Simonaggio, A., Oudard, S. M., & Vano, Y. A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.16 · Cited by 21

PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes

Menasché, B. L., Davis, E. M., Wang, S., Ouyang, Y., Li, S., Yu, H., & Shen, J. (2020) · Science Advances · doi:10.1126/sciadv.abc3243 · Cited by 17

Patient with anomalous skin pigmentation expands the phenotype of ARID2 loss‐of‐function disorder, a SWI/SNF‐related intellectual disability

Khazanchi, R., Ronspies, C., Smith, S. C., & Starr, L. J. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61075 · Cited by 17

Associations of DNA Methylation With Behavioral Problems, Gray Matter Volumes, and Negative Life Events Across Adolescence: Evidence From the Longitudinal IMAGEN Study

Sun, Y., Jia, T., Barker, E. D., Chen, D., Zhang, Z., Xu, J., Chang, S., Zhou, G., Liu, Y., Tay, N., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.06.012 · Cited by 18

Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios

Verano, A. L., You, I., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Fischer, E. S., Wang, E. S., & Gray, N. S. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00439 · Cited by 16

CRISPR/Cas9 screening: unraveling cancer immunotherapy’s ‘Rosetta Stone’

Chen, B., Deng, Y., Ren, X., Zhao, J., & Jiang, C. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.04.014 · Cited by 17

A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors

Rogers, L. M., Wang, Z., Mott, S. L., Dupuy, A. J., & Weiner, G. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0056 · Cited by 16

Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

Hou, T., Jiang, S., Wang, Y., Xie, Y., Zhang, H., Feng, Y., Ma, F., Ma, J., Liu, X., & Hu, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.608300 · Cited by 16

Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity

Park, J. J.-Y., Codina, A., Ye, L., Lam, S. Z., Guo, J., Clark, P. R., Zhou, X., Peng, L., & Chen, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01389-y · Cited by 15

Tumor mutational burden as predictive factor of response to immunotherapy

González‐Cao, M., Viteri, S., Karachaliou, N., Aguilar, A., Garcia, J. J., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.03 · Cited by 15

Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer

Sha, H., Gan, Y., Zou, R., Wu, J., & Feng, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.790967 · Cited by 15

Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies

Hein, K. Z., Stephen, B., & Fu, S. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-37 · Cited by 17

Unveiling major histocompatibility complex-mediated pan-cancer immune features by integrated single-cell and bulk RNA sequencing

Feng, H.-R., Shen, X., Zhu, X., Zhong, W.-T., Zhu, D.-X., Zhao, J., Chen, Y.-J., Shen, F., Liu, K., & Liang, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217062 · Cited by 15

Melanoma genomics – will we go beyond BRAF in clinics?

Mirek, J., Bal, W., & Olbryt, M. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05957-2 · Cited by 19

Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance

Ryser, M. D., Yu, M., Grady, W. M., Siegmund, K. D., & Shibata, D. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-35621-y · Cited by 17

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15

Understanding genetic determinants of resistance to immune checkpoint blockers

Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 16

Mapping the functional network of human cancer through machine learning and pan-cancer proteogenomics

Shi, Z., Lei, J. T., Elizarraras, J. M., & Zhang, B. (2024) · Nature Cancer · doi:10.1038/s43018-024-00869-z · Cited by 16

PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance

Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 14

STUB1 is an intracellular checkpoint for interferon gamma sensing

Ng, S., Lim, S., Sim, A. C. N., Mangadu, R., Lau, A., Zhang, C., Martinez, S. B., Chandramohan, A., Lim, U.-M., Ho, S. S. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18404-4 · Cited by 14

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

Élez, E., Mulet-Margalef, N., Sansó, M., Ruíz‐Pace, F., Mancuso, F. M., Comas, R., Ros, J., Argilés, G., Martini, G., Sanz‐García, E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010118 · Cited by 14

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries

Pipek, O., Vízkeleti, L., Doma, V., Alpár, D., Bödör, C., Kárpáti, S., & Tı́már, J. (2023) · Cancers · doi:10.3390/cancers15061712 · Cited by 14

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice

Li, B. E., Li, G. Y., Cai, W., Zhu, Q., Seruggia, D., Fujiwara, Y., Vakoc, C. R., & Orkin, S. H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009455 · Cited by 14

Characterization of the genomic alterations in poorly differentiated thyroid cancer

Lee, Y., Moon, S., Seok, J. Y., Lee, J., Nam, S., & Chung, Y. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-46466-5 · Cited by 14

Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo

Codina, A., Renauer, P. A., Wang, G., Chow, R. D.-W., Park, J. J.-Y., Ye, H., Zhang, K., Dong, M. B., Gassaway, B. M., Ye, L., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.004 · Cited by 14

CRISPR Screens to Identify Regulators of Tumor Immunity

LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 16

Cancer genes disfavoring T cell immunity identified via integrated systems approach

Kishton, R. J., Patel, S. J., Decker, A. E., Vodnala, S. K., Cam, M., Yamamoto, T. N., Patel, Y. K., Sukumar, M., Yu, Z., Ji, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111153 · Cited by 13

Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer

Ordonez‐Rubiano, S. C., Maschinot, C. A., Wang, S., Sood, S., Baracaldo-Lancheros, L. F., Strohmier, B. P., McQuade, A. J., Smith, B. C., & Dykhuizen, E. C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00671 · Cited by 15

When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors

Yarmarkovich, M., & Maris, J. M. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.006 · Cited by 14

Role of SWI/SNF chromatin remodeling genes in lung cancer development

Monterde, B., & Varela, I. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211084 · Cited by 13

Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements

Lu, Y., Ma, S., Chan, Y.-T., Wu, Y., Feng, Y., & Wang, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.057 · Cited by 15

Defects in DNA damage responses in SWI/SNF mutant cells and their impact on immune responses

Begg, K., Braun, H., Ghaddar, N., Wu, L., & Downs, J. A. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103609 · Cited by 13

Research progress of SWI/SNF complex in breast cancer

Li, K., Wang, B., & Hu, H. (2024) · Epigenetics & Chromatin · doi:10.1186/s13072-024-00531-z · Cited by 14

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249

Abstract 1599: SMARCA4 regulates tumor resistance to anti-tumor immune response

Chaudhri, A., Wang, Y., Shi, L., Rai, K., & Hwu, P. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1599

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 21

Abstract A146: Systematic discovery of immune regulatory mechanisms in tumor cells

Pan, D., Kobayashi, A., Jiang, P., Yuan, G., Liu, X. S., Doench, J. G., Qiu, X., Rao, P. K., Long, H. W., Brown, M. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6074.cricimteatiaacr18-a146

SNF'ing out antitumor immunity

Kiberstis, P. A. (2018) · Science · doi:10.1126/science.359.6377.756-c